1M6MYTD1Y5YMAX
Loading quotes...
Forecast
| Buy |
1 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0.00 | - |
| Gross profit | −20.97k | - |
| Net profit | −5.87m | 61,80% |
| EBITDA | −5.91m | 63,52% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 2.13m€ |
Number of shares | 1.06m |
52-week high/low | 18,02€ - 1,92€ |
| Dividends | No |
Beta | 1,24 |
P/E ratio | −0,05 |
PEG ratio | 0,00 |
P/B ratio | 0,02 |
P/S ratio | 0,00 |
Company profile
| Name | TransCode Therapeutics Inc |
| CEO | Philippe Calais |
| Employees | 12 |
Discover assets
Shareholders of TransCode Therapeutics Inc also invest in the following assets
